Hubert Lam, Vice President of Preclinical Development
Professional Overview
Hubert Lam is an accomplished pharmaceutical executive with over 15 years of experience in preclinical development and vaccine research. As the Vice President of Preclinical Development at Affini-T Therapeutics, he oversees all aspects of the company's preclinical pipeline, driving the advancement of innovative cancer immunotherapies from discovery to investigational new drug application.
Experience Summary
Current Role
As Vice President of Preclinical Development at Affini-T Therapeutics, Hubert is responsible for leading a team of scientists and researchers in the design, development, and optimization of the company's preclinical pipeline. He plays a key role in defining strategic research priorities, managing cross-functional collaborations, and ensuring the successful translation of novel therapeutic candidates from the lab to the clinic. Under his leadership, Affini-T has advanced multiple first-in-class cancer immunotherapies into IND-enabling studies.
Career Progression
Prior to joining Affini-T, Hubert held progressive leadership roles at Genocea Biosciences, where he spearheaded the development of next-generation T-cell vaccines and immunotherapies. As the Senior Director and Director of Preclinical Development, he successfully advanced multiple programs from discovery through IND-enabling studies, contributing to the company's pipeline growth and strategic partnerships.
Hubert's early career was marked by his contributions to the field of vaccine research and development. He held roles at Sanofi Pasteur, where he managed the discovery and development of novel bacterial vaccine candidates, and served as a post-doctoral fellow at Harvard Medical School, where he conducted groundbreaking research on the host-pathogen interactions.
Academic Background
Hubert holds a Ph.D. in Microbiology from Yale University, where his graduate research focused on the molecular mechanisms of bacterial pathogenesis. He also completed a post-doctoral fellowship at Harvard Medical School, further honing his expertise in immunology and vaccine development.
Areas of Expertise
- Preclinical development of immunotherapies and vaccines
- Immunology and host-pathogen interactions
- Translational research and IND-enabling studies
- Cross-functional team management and collaboration
- Strategic planning and pipeline prioritization
Professional Impact
Hubert's contributions to the field of preclinical development and vaccine research have been widely recognized. He has co-authored numerous peer-reviewed publications and presented his work at prestigious scientific conferences. His leadership and technical expertise have been instrumental in advancing multiple innovative therapeutic candidates through the preclinical stage and into clinical trials.
Conclusion
With his extensive experience in the pharmaceutical industry and strong academic background, Hubert Lam is a highly respected leader in the field of preclinical development. As the Vice President of Preclinical Development at Affini-T Therapeutics, he continues to drive the advancement of novel cancer immunotherapies, contributing to the company's mission of improving patient outcomes and transforming the standard of care.
